AN2 Therapeutics, Inc.
ANTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $31,983 | $40,873 | $41,239 |
| - Cash | $18,003 | $18,220 | $19,985 | $21,351 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $13,763 | $20,888 | $19,888 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$9,353 | -$7,216 | -$11,537 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$9,353 | -$6,462 | -$10,649 | -$7,522 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.31 | -0.21 | -0.35 | -0.25 |
| % Growth | -47.6% | 40% | -40% | – |
| Operating Cash Flow | -$6,375 | -$7,599 | -$10,624 | -$5,273 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,375 | -$7,599 | -$10,624 | -$5,273 |